WO2013048130A3 - Binding molecule for neutralizing rabies virus - Google Patents

Binding molecule for neutralizing rabies virus Download PDF

Info

Publication number
WO2013048130A3
WO2013048130A3 PCT/KR2012/007795 KR2012007795W WO2013048130A3 WO 2013048130 A3 WO2013048130 A3 WO 2013048130A3 KR 2012007795 W KR2012007795 W KR 2012007795W WO 2013048130 A3 WO2013048130 A3 WO 2013048130A3
Authority
WO
WIPO (PCT)
Prior art keywords
rabies virus
binding molecule
neutralizing
neutralizing rabies
species
Prior art date
Application number
PCT/KR2012/007795
Other languages
French (fr)
Korean (ko)
Other versions
WO2013048130A2 (en
Inventor
장신재
김판겸
김만수
박현진
Original Assignee
(주)셀트리온
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)셀트리온 filed Critical (주)셀트리온
Priority to CN201280047216.2A priority Critical patent/CN103998059B/en
Publication of WO2013048130A2 publication Critical patent/WO2013048130A2/en
Publication of WO2013048130A3 publication Critical patent/WO2013048130A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Abstract

The present invention relates to a binding molecule for neutralizing a rabies virus. More specifically, the binding molecule according to the present invention, can neutralize the rabies virus that is derived from species such as bats, dogs, cows, mongooses, skunks, and wolves, and thus can be useful in treating a patient that has contracted the rabies virus derived from a wide variety of species.
PCT/KR2012/007795 2011-09-30 2012-09-27 Binding molecule for neutralizing rabies virus WO2013048130A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280047216.2A CN103998059B (en) 2011-09-30 2012-09-27 For in and the binding molecule of rabies virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110099685 2011-09-30
KR10-2011-0099685 2011-09-30

Publications (2)

Publication Number Publication Date
WO2013048130A2 WO2013048130A2 (en) 2013-04-04
WO2013048130A3 true WO2013048130A3 (en) 2013-05-23

Family

ID=47996620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007795 WO2013048130A2 (en) 2011-09-30 2012-09-27 Binding molecule for neutralizing rabies virus

Country Status (3)

Country Link
KR (1) KR101495019B1 (en)
CN (1) CN103998059B (en)
WO (1) WO2013048130A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088256A1 (en) * 2013-12-12 2015-06-18 (주)셀트리온 Binding molecules capable of neutralizing rabies viruses
CN107709360B (en) * 2015-06-10 2021-10-19 赛特瑞恩股份有限公司 Rabies virus G protein epitope and binding molecule specifically bound with same and used for neutralizing rabies virus
BR112021008240A2 (en) 2018-11-02 2021-10-26 Cadila Healthcare Limited MONOCLONAL ANTIBODIES, COCKTAIL OF AT LEAST TWO MONOCLONAL ANTIBODIES, COMBINATION OF A MONOCLONAL ANTIBODY OR A COCKTAIL OF AT LEAST TWO MONOCLONAL MURINE ANTIBODIES AND AN ANTIRABIC VACCINE, USE OF A MONOCLONAL ANTIBODY OR A COCKTAIL OF AT LEAST TWO MONOCLONAL MURINE ANTIBODIES , COMPOSITION, SET, METHOD, METHODS TO DIAGNOSE AND DETECT RABIES AND PROCESSES FOR PRODUCTION AND PURIFICATION OF AN ANTIBODY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695757A (en) * 1993-05-26 1997-12-09 Thomas Jefferson University Methods for treating post-exposure rabies and anti-rabies compositions
US20060216300A1 (en) * 2003-06-13 2006-09-28 Thomas Jefferson University Recombinant antibodies and compositions and methods for making and using the same
US20070072177A1 (en) * 2004-05-27 2007-03-29 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
US20090041777A1 (en) * 2005-02-02 2009-02-12 Thomas Jr William D Human antibodies against rabies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
CN101696242B (en) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 Human anti rabies virus neutralizing antibody Fab as well as preparation method and application thereof
CN101812130B (en) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing antibody (RVFab5) against rabies virus glycoprotein
CN102643343B (en) * 2011-02-17 2015-03-25 长春百克生物科技股份公司 Human derived anti-rabies virus glycoprotein gene engineering antibody and preparation and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695757A (en) * 1993-05-26 1997-12-09 Thomas Jefferson University Methods for treating post-exposure rabies and anti-rabies compositions
US20060216300A1 (en) * 2003-06-13 2006-09-28 Thomas Jefferson University Recombinant antibodies and compositions and methods for making and using the same
US20070072177A1 (en) * 2004-05-27 2007-03-29 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
US20090041777A1 (en) * 2005-02-02 2009-02-12 Thomas Jr William D Human antibodies against rabies and uses thereof

Also Published As

Publication number Publication date
CN103998059B (en) 2016-01-20
WO2013048130A2 (en) 2013-04-04
CN103998059A (en) 2014-08-20
KR101495019B1 (en) 2015-02-24
KR20130036150A (en) 2013-04-11

Similar Documents

Publication Publication Date Title
WO2013040492A3 (en) Methods for treating hcv
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
WO2012109373A3 (en) Treatment of osteoarthritis and pain
WO2012083048A3 (en) Anti-viral compounds
WO2014052836A3 (en) Methods and compositions for treating infection
WO2012129341A3 (en) Disease detection in plants
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2013109974A3 (en) Anti-cxcr3 antibodies
WO2012135177A3 (en) Methods and compositions for cytomegalovirus il-10 protein
HK1208364A1 (en) Method for treating hepatitis c virus infection using quercetin- containing compositions
WO2010032011A3 (en) Anti-fungal therapy
WO2012017321A3 (en) Treatment for dyslipidemia
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
WO2013120022A3 (en) Treatment of hypoglycemia
WO2012162580A3 (en) Anti-viral compounds
WO2010089554A8 (en) Grass peptides for vaccine
WO2012162578A3 (en) Anti-viral compounds
WO2010098583A2 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2013048130A3 (en) Binding molecule for neutralizing rabies virus
WO2013152274A8 (en) Epitope- scaffold immunogens against respiratory syncytial virus (rsv)
EA201491581A1 (en) ВЕЗИКУЛЯРНЫЕ КОМПОЗИЦИИ
WO2012139097A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2814498A4 (en) Guanosine-rich oligonucleotide (gro) compositions, methods and uses for treating respiratory syncytial virus infection
WO2012162471A3 (en) Pachycereus plant extract and methods of use thereof
WO2012131719A3 (en) A herbal formulation for treatment of silent estrus in animals

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12837417

Country of ref document: EP

Kind code of ref document: A2